Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04353401 · ClinicalTrials.gov registry record

WGS Analysis of COVID-19 Positive Patients

A clinical trial of COVID-19 and Coronavirus Infection, sponsored by Vanda Pharmaceuticals.

Completed
Registry status
79
Enrollment target
1
Study location

NCT04353401 is a study of COVID-19 and Coronavirus Infection that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 79 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04353401, a study of COVID-19 and Coronavirus Infection, has completed, sponsored by Vanda Pharmaceuticals.

COMPLETED
Registry status
79 participants
Enrollment target
1
Study location

Study Summary

We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.

Study Locations (1)

Ohio

  • Vanda Investigational Site - Cleveland

Trial Details

FieldValue
Enrollment Target 79 participants
Start Date 2020-08-03
Est. Completion 2022-03-09

Sponsor

Vanda Pharmaceuticals

68 total trials

What the Registry Record Tells You About NCT04353401

The ClinicalTrials.gov registry entry for NCT04353401 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.

NCT04353401 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04353401 about?

NCT04353401 is a clinical study titled "WGS Analysis of COVID-19 Positive Patients". We aim to better understand the mode of action of COVID-19 in the context of its interaction with the host genome through whole-genome sequencing.

What is the current status of trial NCT04353401?

This trial is currently completed. The enrollment target is 79 participants. The study started on 2020-08-03. Estimated completion is 2022-03-09.

What conditions does trial NCT04353401 study?

This clinical trial studies the following conditions: COVID-19, Coronavirus Infection.

Who is sponsoring clinical trial NCT04353401?

This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04353401 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.